Pliant Therapeutics Inc

NASDAQ:PLRX   3:59:51 PM EDT
8.74
+0.56 (+6.78%)
Products, Strategic Combinations

Pliant Therapeutics Announces Advancement Of Integrin Target In Fibrosis Under Strategic Collaboration

Published: 06/16/2022 12:13 GMT
Pliant Therapeutics Inc (PLRX) - Announces Advancement of Integrin Target in Fibrosis Under Strategic Collaboration.
Pliant Therapeutics-under Terms Co Will Receive a $4 Million Milestone Payment and Research Funding to Support Initiation of Development Work on Target.
Any New Product Candidates Directed to Target Will Be Subject to Milestones and Royalties Payable to Pliant.
Pliant-advancement of Fibrosis-directed Integrin Target Into Development As Part of Co's 2019 Research and Development Collaboration With Novartis.